Omega Therapeutics' Epigenomic Medicines Show Promising Results in Reducing MYC Expression in Cancer Patients
Omega Therapeutics has released the initial data from a clinical trial of its epigenomic controllers, which aim to repress the MYC gene associated with various cancers. The trial tested two doses of the therapy in eight patients with hepatocellular carcinoma or other solid tumors where MYC is often involved, showing a 55% reduction in MYC expression.